Benzodiazepines produce a variety of effects by binding to the benzodiazepine receptor site and magnifying the efficiency and effects of the neurotransmitter gamma aminobutyric acid (GABA) by acting on its receptors. As this site is the most prolific inhibitory receptor set within the brain, its modulation results in the sedating (or calming effects) of Clonazolam on the nervous system.
The anticonvulsant properties of benzodiazepines may be, in part or entirely, due to binding to voltage-dependent sodium channels (VDSC) rather than benzodiazepine receptors. Clonazolam is hydroxylated, and is mainly reduced to the 7-amino benzodiazepine and then acetylated.
Clonazolam is reported to be similar to alprazolam and other benzodiazepines that suppress emotions and produce moderate-strong feelings of relaxation, pleasure and comfort in the body. This seems to present itself more often in those with pre-existing anxiety. Many anecdotal reports from users of this compound have stated it as being one of the most euphoric benzodiazepines.
The cognitive effects of clonazolam are thought to be mainly amnesic, but also include most other typical effects seen with benzodiazepines. Clonazolam is reported to cause "blackouts" at a higher rate than other benzodiazepines.
- Preparation methods
- Volumetric liquid dosing** - If one's benzodiazepines are in powder form, they are unlikely to weigh out accurately without the most expensive of scales due to their extreme potency. Clonazolam is especially important to weigh out and volumetrically dose properly due to it being active in the microgram range. To avoid adverse effects, one can dissolve the benzodiazepine volumetrically into a solution and dose it accurately based upon the methodological instructions linked within this tutorial here.
low toxicity relative to dose. However,potentially lethal when mixed with depressants like alcohol or opioids.
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
-extremely physically and psychologically addictive.
Tolerance will develop to the sedative-within a couple of days of continuous use. After cessation,7 - 14 days. However, in certain cases, this may take significantly longer in a manner which is proportional to the duration and intensity of one's long-term usage.
Clonazolam presents cross-tolerance with Cross-all benzodiazepines, meaning that after its consumption all benzodiazepines will have a reduced effect.
Discontinuation and withdrawal
Overdose
Czech Republic: Clonazolam is a Schedule I (List 4) substance. Used exclusively for limited research purposes or very limited therapeutic purposes. (§ 1, d), 2. of Nařízení vlády č. 463/2013 Sb.)
Germany: Clonazolam is controlled under the BTMG (Betäubungsmittelgesetz) in the Anlage II as of November 11, 2021. Production and import with the aim to place it on the market, administration to another person, possession and trading are illegal.
Japan: Clonazolam is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
Poland: Clonazolam is a NPS class drug in Poland, making it illegal to possess or distribute.
Russia: Clonazolam is a Schedule III controlled substance since 2017.
Sweden: Clonazolam is classified as an addictive. Production, import, trading and possesion require a special permission.
Switzerland: Clonazolam is a controlled substance specifically named under Verzeichnis E.
The Netherlands: Clonazolam is a List 2 substance of the Opium Law, making it illegal.
United Kingdom: Clonazolam is a Class C drug in the UK as of 31st May 2017 and is illegal to possess, produce or supply.
United States: Clonazolam is a Schedule I controlled substance as of January 23, 2023.
Oregon:** Clonazolam is now classified as a Schedule I substance in the state of Oregon.
Virginia: Clonazolam is now classified as a Schedule I substance in the state of Virginia.
Responsible use
Volumetric liquid dosing
Research chemical
Depressant
Benzodiazepines
Alcohol
Clonazolam (Wikipedia)
Clonazolam (Isomer Design)
Clonazolam (DrugBank)
Community Observations on Pharmacological Properties
Online communities consistently describe clonazolam as one of the most potent and euphorically active benzodiazepines encountered in the research chemical market. Users frequently compare it to alprazolam (Xanax) but describe it as significantly more potent per milligram and more likely to produce euphoria, particularly in individuals with pre-existing anxiety.
A critical pharmacological observation from community experience is the extremely steep dose-response curve of clonazolam. Users report that the difference between a therapeutic-feeling dose and a blackout-inducing dose can be as little as 0.125-0.25 mg. This narrow margin is a primary factor in the substance's reputation for causing harm.
Community members also report that clonazolam produces unusually rapid and severe physical dependence compared to other benzodiazepines. Users describe developing significant dependence after as little as 1-2 weeks of daily use at moderate doses, with withdrawal symptoms that can include severe rebound anxiety, insomnia, tremors, and in severe cases, seizures. Multiple community reports describe tolerance escalating to extraordinary levels — some users report tolerances exceeding 100 mg of etizolam or equivalent doses of other benzodiazepines after extended clonazolam use, suggesting that clonazolam may produce cross-tolerance at an accelerated rate compared to pharmaceutical benzodiazepines.
Clonazolam can be administered via oral. The route of administration can influence both the onset and intensity of muscle relaxation.